Woodline Partners’s Lyell Immunopharma LYEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $870K | Buy |
+98,425
| New | +$870K | ﹤0.01% | 816 |
|
|
2024
Q3 | – | Sell |
-1,037
| Closed | -$30.1K | – | 661 |
|
|
2024
Q2 | $30.1K | Hold |
1,037
| – | – | ﹤0.01% | 542 |
|
|
2024
Q1 | $46.3K | Hold |
1,037
| – | – | ﹤0.01% | 524 |
|
|
2023
Q4 | $40.2K | Hold |
1,037
| – | – | ﹤0.01% | 464 |
|
|
2023
Q3 | $30.5K | Hold |
1,037
| – | – | ﹤0.01% | 579 |
|
|
2023
Q2 | $66K | Hold |
1,037
| – | – | ﹤0.01% | 609 |
|
|
2023
Q1 | $48.9K | Hold |
1,037
| – | – | ﹤0.01% | 614 |
|
|
2022
Q4 | $72K | Hold |
1,037
| – | – | ﹤0.01% | 712 |
|
|
2022
Q3 | $152K | Buy |
+1,037
| New | +$152K | ﹤0.01% | 659 |
|
|
2022
Q2 | – | Sell |
-10,090
| Closed | -$1.02M | – | 846 |
|
|
2022
Q1 | $1.02M | Hold |
10,090
| – | – | 0.02% | 463 |
|
|
2021
Q4 | $1.56M | Sell |
10,090
-204
| -2% | -$31.6K | 0.02% | 447 |
|
|
2021
Q3 | $3.05M | Sell |
10,294
-14,684
| -59% | -$4.35M | 0.05% | 333 |
|
|
2021
Q2 | $8.11M | Buy |
+24,978
| New | +$8.11M | 0.15% | 159 |
|